Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;8(10):803-805.
doi: 10.1016/S2213-8587(20)30311-9.

SGLT2 inhibitors and renal complications in type 1 diabetes

John R Petrie  1
Affiliations
Comment

SGLT2 inhibitors and renal complications in type 1 diabetes

John R Petrie. Lancet Diabetes Endocrinol. 2020 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Petrie JR. SGLT2 inhibitors in type 1 diabetes: knocked down, but up again? Lancet Diabetes Endocrinol. 2017;5:841–843. - PubMed
    1. Livingstone SJ, Levin D, Looker HC. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313:37–44. - PMC - PubMed
    1. Lo KB, Gul F, Ram P. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10:1–10. - PubMed
    1. Groop P-H, Dandona P, Phillip M. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8:845–854. - PubMed
    1. Mathieu C, Dandona P, Birkenfeld AL. Benefit:risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and BMI ≥27 kg/m2. Diabetes Obes Metab. 2020 doi: 10.1111/dom.14144. published online July 30. - DOI - PMC - PubMed